Viridian Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclona...
Latest News
8 days ago · seekingalpha.com
Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans TranscriptViridian Therapeutics, Inc. ( VRDN ) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans November 9, 2026 8:00 AM EST Company Participants Greg Rossino Stephen Mahoney - CEO, President & Director Radhika Tripuraneni - Chief Medical Officer Shan Wu - Chief Business Officer Conference Call Participants Faisal Khurshid - Jefferies LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Thomas Smith - Leerink Partners LLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Joseph Thome - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Dina Elmonshed - UBS Investment Bank, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Anish Nikhanj - Truist Securities, Inc., Research Division Qiu Wu - Goldman Sachs Group, Inc., Research Division John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics Conference Call.
8 days ago · benzinga.com
Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week DosingViridian Therapeutics Inc. (NASDAQ:VRDN) reported positive Phase 1 clinical trial results for VRDN-008, highlighting its pharmacokinetic and pharmacodynamic profile as a potential best-in-class subcutaneous treatment for autoimmune and rare diseases.
8 days ago · businesswire.com
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous DosingWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008. “Today's VRDN-008 data exceeded expectations and demonstrates a potentially transformative FcRn-inhibitor profile. Based on these data, we believe VRDN-008 dosed subcutaneously every 8 weeks can deliver deep and sustain.
10 days ago · businesswire.com
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1 clinical trial in healthy volunteers and development plans for its neonatal Fc receptor (FcRn) portfolio on Monday, November 9, 2026, at 8:00 a.m. ET. Conference Call and.
11 days ago · zacks.com
Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should KnowThe average of price targets set by Wall Street analysts indicates a potential upside of 39.7% in Viridian Therapeutics (VRDN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
12 days ago · seekingalpha.com
Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data AheadViridian Therapeutics delivered a strong Q3, with Lumvoa net sales of $24.7 million, far surpassing consensus expectations. Competition is intensifying with Roche's Enspryng entering the TED market, but I see Lumvoa as well-positioned for continued growth, with more growth expected to come from elegrobart in late 2027. VRDN's near-term focus is on phase 1 data for VRDN-008 in the FcRn franchise, with expectations for deep IgG lowering and good safety and tolerability.
12 days ago · marketbeat.com
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings CallViridian Therapeutics NASDAQ: VRDN reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment's first quarter on the market, with more than 100 patients having received at least one infusion by Sept. 30.
13 days ago · seekingalpha.com
Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call TranscriptViridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript
13 days ago · zacks.com
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue EstimatesViridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to a loss of $0.34 per share a year ago.
13 days ago · businesswire.com
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business ProgressWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30, 2026. "We are highly encouraged by the strength of Lumvoa's early launch in TED, which has exceeded expectations," said Steve Mahoney, President and Chief Executive Offi.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VRDN